MedTrace Logo

AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis

NCT01228396 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-08-18

No results posted yet for this study

Summary

Patients with marked bladder dysfunction as a result of secondary progressive multiple sclerosis are being recruited to receive AIMSPRO or placebo by subcutaneous injection, in this double-blind crossover study.

Conditions

  • Secondary Progressive Multiple Sclerosis

Interventions

DRUG

Hyperimmune caprine serum against HIV lysate

1.0ml solution for subcutaneous injection (4.5mg total protein / ml) twice weekly for 4 weeks

Sponsors & Collaborators

  • Daval International Limited

    lead INDUSTRY

Principal Investigators

  • James Malone-Lee, MD · University College, London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2011-05-31
Completion
2012-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01228396 on ClinicalTrials.gov